Travere Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Travere Therapeutics Inc TVTX.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -91 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -56 cents to -5 cents per share.

• Revenue rose 111.5% to $114.45 million from a year ago; analysts expected $100.64 million.

• Travere Therapeutics Inc's reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $12.76 million.

• Travere Therapeutics Inc shares had risen by 12.7% this quarter and lost 4.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 7.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Travere Therapeutics Inc is $30.00, about 44.4% above its last closing price of $16.68

This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)